Dedicated to deliver first-in-class medical devices and pharmaceuticals for local bone healing
Osteo-Pharma BV was founded in 2014 and develops novel products for orthopedic and dental applications for the local treatment of bone fractures and bone defects. Products in development are based on our proprietary OsteoActivatorTM technology.
This technology involves encapsulating ancillary amounts of low molecular weight bone healing compounds in a biodegradable carrier resulting in a local sustained release of these compounds over a 4-6-week period. During this period bone formation is enhanced and bone resorption is inhibited simultaneously, resulting in a net effect of increased bone growth. Our lead product, OsteoActivator-P, has been approved by an accredited Medical Research Ethics Committee (MREC) and will be subject of a dental clinical study starting mid-2021 in the Netherlands. In addition, preclinical studies on improved bone fracture healing and the treatment of impaired bone remodeling in osteoarthritis are ongoing. Preclinical studies with OsteoActivator coated implants that improve osseo-integration to prevent implant loosening, have successfully been completed.
Osteo-Pharma today announced that it has successfully obtained MREC approval for testing their lead product, OsteoActivator-P, in patients. OsteoActivator-P is a novel coated porcine collagen barrier membrane that will be placed on a dental defect to improve early bone formation.
OSTEOACTIVATORTM TECHNOLOGY PLATFORM
BONE FRACTURE FACTS